First Time Loading...

Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390

Watchlist Manager
Guizhou Xinbang Pharmaceutical Co Ltd Logo
Guizhou Xinbang Pharmaceutical Co Ltd
SZSE:002390
Watchlist
Price: 3.84 CNY -1.03% Market Closed
Updated: May 21, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

9.2B
-4%
Assets
Growth Rates:
1 Year
-6%
3 Years
-4%
5 Years
-15%
7 Years
-14%
10 Years
+522%
2.4B
-13%
Liabilities
Growth Rates:
1 Year
-20%
3 Years
-50%
5 Years
-59%
7 Years
-46%
10 Years
+429%
6.9B
-0.2%
Equity
Growth Rates:
1 Year
+1%
3 Years
+39%
5 Years
+38%
7 Years
+8%
10 Years
+562%

Balance Sheet Decomposition
Guizhou Xinbang Pharmaceutical Co Ltd

9.2B
Assets
2.4B
Liabilities
9.2B
Assets
2.4B
Liabilities
Current Assets 5.4B
Cash & Short-Term Investments 730.7m
Receivables 3.4B
Other Current Assets 1.3B
Non-Current Assets 3.8B
Long-Term Investments 375.5m
PP&E 2.5B
Intangibles 783.9m
Other Non-Current Assets 156m
Current Liabilities 2.1B
Accounts Payable 654.6m
Accrued Liabilities 37.3m
Short-Term Debt 1.1B
Other Current Liabilities 308.3m
Non-Current Liabilities 334m
Long-Term Debt 21.1m
Other Non-Current Liabilities 312.9m

Balance Sheet
Guizhou Xinbang Pharmaceutical Co Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
659
603
1 674
2 145
1 614
1 236
1 710
0
0
731
Cash
1
2
1
1
7
2
1
0
0
731
Cash Equivalents
658
601
1 673
2 144
1 607
1 234
1 709
0
0
0
Total Receivables
1 595
2 048
2 770
3 040
3 613
3 474
3 209
3 682
3 540
3 361
Accounts Receivables
1 058
1 471
2 203
2 407
2 705
2 803
2 415
2 892
2 913
2 875
Other Receivables
537
577
567
633
908
671
794
791
627
486
Inventory
545
615
744
700
1 044
994
843
936
1 033
1 001
Other Current Assets
526
561
453
453
401
472
329
445
437
319
Total Current Assets
3 324
3 827
5 641
6 338
6 673
6 175
6 091
5 576
5 806
5 412
PP&E Net
866
1 755
2 360
2 707
2 775
2 751
2 323
2 706
2 672
2 518
PP&E Gross
866
1 755
2 360
2 707
2 775
2 751
2 323
2 706
2 672
2 518
Accumulated Depreciation
295
444
619
739
937
1 148
1 253
1 495
1 702
1 854
Intangible Assets
144
166
349
337
328
308
220
218
204
180
Goodwill
648
648
2 319
2 319
778
778
606
607
607
604
Long-Term Investments
10
30
30
93
88
146
223
347
344
375
Other Long-Term Assets
230
79
98
161
212
261
200
174
160
156
Other Assets
648
648
2 319
2 319
778
778
606
607
607
604
Total Assets
5 223
N/A
6 505
+25%
10 797
+66%
11 955
+11%
10 854
-9%
10 419
-4%
9 662
-7%
9 629
0%
9 794
+2%
9 245
-6%
Liabilities
Accounts Payable
591
982
955
958
783
835
600
738
712
655
Accrued Liabilities
5
29
39
29
37
46
39
47
36
37
Short-Term Debt
1 876
2 502
3 033
3 633
4 298
3 709
3 598
1 646
1 634
1 058
Current Portion of Long-Term Debt
77
0
0
0
0
25
0
0
3
4
Other Current Liabilities
159
259
258
254
220
394
233
323
303
304
Total Current Liabilities
2 709
3 772
4 284
4 874
5 337
5 009
4 470
2 755
2 687
2 059
Long-Term Debt
0
17
0
298
323
299
0
25
22
21
Deferred Income Tax
0
0
0
0
0
0
0
0
1
1
Minority Interest
61
127
133
143
201
211
250
209
257
290
Other Liabilities
57
47
28
24
25
63
23
21
19
22
Total Liabilities
2 826
N/A
3 963
+40%
4 445
+12%
5 340
+20%
5 887
+10%
5 582
-5%
4 744
-15%
3 009
-37%
2 985
-1%
2 393
-20%
Equity
Common Stock
500
1 251
1 705
1 705
1 667
1 667
1 667
2 027
1 944
1 944
Retained Earnings
412
557
751
1 019
309
72
82
355
463
633
Additional Paid In Capital
1 485
734
3 907
3 907
3 624
3 624
3 624
4 693
4 402
4 403
Treasury Stock
0
0
0
0
0
369
455
455
0
127
Other Equity
0
0
11
16
15
13
0
0
0
0
Total Equity
2 397
N/A
2 542
+6%
6 352
+150%
6 615
+4%
4 967
-25%
4 837
-3%
4 918
+2%
6 620
+35%
6 808
+3%
6 852
+1%
Total Liabilities & Equity
5 223
N/A
6 505
+25%
10 797
+66%
11 955
+11%
10 854
-9%
10 419
-4%
9 662
-7%
9 629
0%
9 794
+2%
9 245
-6%
Shares Outstanding
Common Shares Outstanding
1 251
1 251
1 705
1 705
1 667
1 599
1 584
1 944
1 944
1 916

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 139,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.